<DOC>
	<DOCNO>NCT00122655</DOCNO>
	<brief_summary>The aim trial evaluate impact fat distribution switch NRTI-sparing regimen lipoatrophic antiretroviral experienced patient complete viral suppression . Maintenance virological suppression immunological factor also assess .</brief_summary>
	<brief_title>Study Evaluating Impact Fat Distribution Nucleoside Reverse Transcriptase Inhibitor ( NRTI ) -Sparing Regimens Antiretroviral Experienced Patients With Lipoatrophy</brief_title>
	<detailed_description>Limitations achieve complete HIV eradication render necessary maintain highly active antiretroviral treatment long period , may lead development antiretroviral-associated toxicity . The current standard-of-care HAART regimens include backbone 2 nucleoside reverse transcriptase inhibitor ( NRTIs ) . Many study demonstrate NRTIs particularly thymidine analogue nucleoside important contributor development lipoatrophy . This antiretroviral family inhibits also mitochondrial gamma-DNA polymerase , lead mitochondrial dysfunction side effect peripheral neuropathy , pancreatitis liver dysfunction .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<criteria>Males nonpregnant female Confirmed laboratory diagnosis HIV infection Patients receive 2 3 NRTIcontaining antiretroviral treatment least 3 month Viral load 400 copies/ml Patients clinical peripheral lipoatrophy isolate associated lipohypertrophy self report patient confirm physical examination Current antiretroviral therapy 3 class antiretroviral therapy Previous virologic failure nonnucleoside reverse transcriptase inhibitor ( NNRTI ) protease inhibitor ( PI ) Intolerance nevirapine efavirenz Acute opportunistic infection Diabetes Transaminase level 5 time upper normal limit Hepatitis B virus ( HBV ) coinfection patient receive lamivudine therapy Ongoing immunotherapy include interleukin2 ( IL2 ) interferon Pregnancy plan pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>HIV Lipodystrophy Syndrome</keyword>
</DOC>